With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark

With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Alexandra Pecci · 2026-06-09

Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardio metabolic portfolio.

Source: PharmaVoice